The use of botulinum toxin type A in the treatment of HTLV-1-associated overactive bladder refractory to conventional therapy

AUTOR(ES)

Carneiro Neto, José Abraão, Bittencourt, Valéria Gusmão, de Oliveira, Cassius, Andrade, Rosana, de Carvalho, Edgar Marcelino

FONTE

Rev. Soc. Bras. Med. Trop.

DATA DE PUBLICAÇÃO

2014-08

RESUMO

Urinary symptoms occur in 19% of human T-cell lymphotropic virus type 1 (HTLV-1)-infected patients who do not fulfill criteria for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and in almost 100% of HAM/TSP patients. Few studies have evaluated therapies for overactive bladder (OAB) caused by HTLV-1 infection. This case report describes the effect of onabotulinum toxin A on the urinary manifestations of three patients with HAM/TSP and OAB symptoms. The patients were intravesically administered 200 units of Botox®. Their incontinence episodes improved, and their OAB symptoms scores (OABSS) reduced significantly. These data indicate that Botox® should be a treatment option for OAB associated with HTLV-1 infection.

Documentos Relacionados

• Efficacy of botulinum toxin type A 100 units versus 200 units for treatment of refractory idiopathic overactive bladder
• RE: Efficacy of botulinum toxin type A 100 units versus 200 units for treatment of refractory idiopathic overactive bladder
• Electromotive drug administration for treatment of therapy-refractory overactive bladder
• Polymorphism in the interleukin-10 gene is associated with overactive bladder phenotype associated with HTLV-1 infection
• HTLV-1-associated infective dermatitis and probable HTLV-1- associated myelopathy in an adolescent female